Impact of prehabilitation during neoadjuvant chemotherapy and interval cytoreductive surgery on ovarian cancer patients: a pilot study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1477-7819
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Impact of prehabilitation during neoadjuvant chemotherapy and interval cytoreductive surgery on ovarian cancer patients: a pilot study ; volume:20 ; number:1 ; day:23 ; month:2 ; year:2022 ; pages:1-10 ; date:12.2022
World journal of surgical oncology ; 20, Heft 1 (23.2.2022), 1-10, 12.2022
- Urheber
-
Miralpeix, Ester
Sole-Sedeno, Josep-Maria
Rodriguez-Cosmen, Cristina
Taus, Alvaro
Muns, Maria-Dolors
Fabregó, Berta
Mancebo, Gemma
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12957-022-02517-1
- URN
-
urn:nbn:de:101:1-2022052520491502573275
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:36 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Miralpeix, Ester
- Sole-Sedeno, Josep-Maria
- Rodriguez-Cosmen, Cristina
- Taus, Alvaro
- Muns, Maria-Dolors
- Fabregó, Berta
- Mancebo, Gemma
- SpringerLink (Online service)
Ähnliche Objekte (12)
A mouse model of neoadjuvant chemotherapy followed by interval cytoreductive surgery indicates impaired efficacy of perioperative cisplatin
Neoadjuvant chemotherapy is associated with a high rate of perioperative blood transfusion at the time of interval cytoreductive surgery
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) as a neoadjuvant therapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
Neoadjuvant chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: a feasibility and safety study
Neoadjuvant chemotherapy does not improve survival for patients with high volume colorectal peritoneal metastases undergoing cytoreductive surgery
Interval between secondary cytoreductive surgery and adjuvant chemotherapy is not associated with survivals in patients with recurrent ovarian cancer
Primary Versus Interval Cytoreductive Surgery in Treatment of Advanced Ovarian Cancer
Peritoneal carcinomatosis treated with cytoreductive surgery and intraperitoneal chemotherapy
Neoadjuvant chemotherapy followed by interval debulking surgery for advanced epithelial ovarian cancer: GOTIC-019 study
Preoperative (neoadjuvant) chemotherapy : with 49 tables
Neoadjuvant Chemotherapy for Advanced Ovarian Cancer
Neoadjuvant systemic and hyperthermic intraperitoneal chemotherapy combined with cytoreductive surgery for gastric cancer patients with limited peritoneal metastasis: a prospective cohort study
A mouse model of neoadjuvant chemotherapy followed by interval cytoreductive surgery indicates impaired efficacy of perioperative cisplatin
Neoadjuvant chemotherapy is associated with a high rate of perioperative blood transfusion at the time of interval cytoreductive surgery
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) as a neoadjuvant therapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
Neoadjuvant chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: a feasibility and safety study
Neoadjuvant chemotherapy does not improve survival for patients with high volume colorectal peritoneal metastases undergoing cytoreductive surgery
Interval between secondary cytoreductive surgery and adjuvant chemotherapy is not associated with survivals in patients with recurrent ovarian cancer
Primary Versus Interval Cytoreductive Surgery in Treatment of Advanced Ovarian Cancer
Peritoneal carcinomatosis treated with cytoreductive surgery and intraperitoneal chemotherapy
Neoadjuvant chemotherapy followed by interval debulking surgery for advanced epithelial ovarian cancer: GOTIC-019 study
Preoperative (neoadjuvant) chemotherapy : with 49 tables
Neoadjuvant Chemotherapy for Advanced Ovarian Cancer
Neoadjuvant systemic and hyperthermic intraperitoneal chemotherapy combined with cytoreductive surgery for gastric cancer patients with limited peritoneal metastasis: a prospective cohort study
A mouse model of neoadjuvant chemotherapy followed by interval cytoreductive surgery indicates impaired efficacy of perioperative cisplatin
Neoadjuvant chemotherapy is associated with a high rate of perioperative blood transfusion at the time of interval cytoreductive surgery
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) as a neoadjuvant therapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
Neoadjuvant chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: a feasibility and safety study
Neoadjuvant chemotherapy does not improve survival for patients with high volume colorectal peritoneal metastases undergoing cytoreductive surgery
Interval between secondary cytoreductive surgery and adjuvant chemotherapy is not associated with survivals in patients with recurrent ovarian cancer
Primary Versus Interval Cytoreductive Surgery in Treatment of Advanced Ovarian Cancer
Peritoneal carcinomatosis treated with cytoreductive surgery and intraperitoneal chemotherapy
Neoadjuvant chemotherapy followed by interval debulking surgery for advanced epithelial ovarian cancer: GOTIC-019 study
Preoperative (neoadjuvant) chemotherapy : with 49 tables
Neoadjuvant Chemotherapy for Advanced Ovarian Cancer